

Special Issue

Stewardship of Antibiotics for Multidrug-Resistant Gram-Negative Bacteria

Message from the Guest Editors

In the last decades, multidrug-resistant Gram-negative bacteria (MDR-GNB) have represented an important threat. Recently, some much awaited novel agents have become available, restoring our ability to effectively counteract some perilous infections due to these organisms. However, it remains imperative to administer novel agents thoughtfully and in line with antimicrobial stewardship principles, in order to: (i) delay the development of resistance to novel agents; (ii) delay the diffusion of resistance to novel agents. The present special issue focuses on stewardship of both old and novel antibiotics for MDR-GNB infections. We especially encourage submission of original articles and reviews. However, case reports describing peculiar stewardship situations and decisions in patients with MDR-GNB infections will also be considered. **Keywords:** antimicrobial resistance; MDR; antimicrobial stewardship; multidrug-resistant Gram-negative bacteria; Acinetobacter; Pseudomonas; Klebsiella; KPC; OXA; NDM; IMP; VIM; ESBL

Guest Editors

Dr. Daniele Roberto Giacobbe

Department of Health Sciences (DISSAL), Università degli Studi di Genova, 16132 Genoa, Italy

Dr. Ilias Karaiskos

Department of Internal Medicine – Infectious Diseases, Hygeia Hospital, Athens, Greece

Deadline for manuscript submissions

closed (30 November 2019)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.2
Indexed in PubMed



mdpi.com/si/25674

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.2
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)